KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up – What’s Next?

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) gapped up prior to trading on Monday . The stock had previously closed at $10.61, but opened at $11.30. KalVista Pharmaceuticals shares last traded at $11.77, with a volume of 275,288 shares trading hands.

Analyst Ratings Changes

Several analysts recently commented on KALV shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th.

KalVista Pharmaceuticals Stock Up 9.7 %

The firm has a market capitalization of $503.08 million, a price-to-earnings ratio of -3.33 and a beta of 0.92. The business’s fifty day moving average is $11.60 and its 200 day moving average is $12.09.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. Equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.19 EPS for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the transaction, the chief executive officer now owns 242,527 shares of the company’s stock, valued at $2,912,749.27. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Benjamin L. Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $12.19, for a total value of $89,620.88. Following the sale, the chief executive officer now owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total value of $170,722.15. Following the sale, the chief executive officer now owns 242,527 shares in the company, valued at $2,912,749.27. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,804 shares of company stock valued at $372,112. 10.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter valued at approximately $25,000. EntryPoint Capital LLC acquired a new stake in KalVista Pharmaceuticals in the first quarter valued at $92,000. China Universal Asset Management Co. Ltd. grew its position in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,328 shares during the period. Entropy Technologies LP acquired a new position in shares of KalVista Pharmaceuticals during the 1st quarter worth about $121,000. Finally, SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $153,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).